重组抗人表皮生长因子受体人源化单克隆抗体注射液对Bcap37人乳腺癌细胞生长的抑制作用  

Evaluation of anti-cancer effect of anti-epithelial growth factor receptor monoclonal antibody on human breast cancer Bcap37 cells

作　　者：曹玉婷[1,2] 王珊珊[2] 杨德宣[2] 李琳娜[2] 袁守军[1,2] 

机构地区：[1]安徽医科大学研究生院,合肥230032 [2]军事医学科学院放射与辐射医学研究所,北京100850

出　　处：《安徽医科大学学报》2016年第11期1555-1558,共4页Acta Universitatis Medicinalis Anhui

基　　金：国家重大新药创新科技重大专项综合新药研究开发技术大平台项目(编号:2012ZX09301003-001)

摘　　要：目的观察重组抗人表皮生长因子受体人源化单克隆抗体注射液(MIL41)对Her2高表达人乳腺癌细胞体内外的抑制作用。方法通过流式细胞仪分析人乳腺癌细胞Bcap37中Her2受体的表达量,CCK8法测定MIL41在体外对乳腺癌细胞Bcap37生长的抑制作用;在体内研究中采用人乳腺癌细胞裸鼠皮下移植瘤模型的建立评价MIL41对肿瘤生长的抑制作用。结果体外实验表明Bcap37为Her2受体过表达的人乳腺癌细胞,CCK8法检测结果显示MIL41对受试细胞Bcap37的生长有较强抑制作用。体内实验表明受试药MIL41对受试的人乳腺癌细胞Bcap37的裸鼠皮下移植瘤的生长有明显的抑制效应,同时呈现出良好的浓度依赖关系。分别给予3、6、12 mg/kg不同浓度的受试药,其瘤体积抑制率分别为33.7%、47.8%、59.0%,瘤重抑制率分别为29.6%、44.7%、55.6%。结论 MIL41对Bcap37人乳腺癌细胞在体内外的生长有较强的抑制作用。Objective To investigate the inhibitory effect of anti-epithelial growth factor receptor monoclonal anti- body（ MIL41 ） on human breast cancer Bcap37 cell line in vitro and in vivo. Methods The flow cytometry instru- ment was used to evaluate the level of Her2 expression in Bcap37 cells,the anti-cancer activity of MIL41 in vitro by CCK8 inspection, while the activity in vivo was evaluated by subcutaneous implanted tumors in nude mice model. Results In vitro experiments showed the over-expression of Her2 in human breast cancer Beap37 cells, meanwhile, the replicated CCK8 inspection showed the MIL41 had inhibitory effect in Bcap37 cells. The results showed that MIL41 had strong inhibitory effect in dose-dependent manner on human breast cancer Bcap37 xenotransplanted in nude mice. The inhibition rates of tumor volume were 33.7% ,47.8% and 59.0% when the administrated concentration was 3,6,12 mg/kg; moreover, the inhibition rates of tumor weight were 29.6% ,44. 7% and 55.6%. Conclusion MIL41 could efficiently inhibit the proliferation of human breast cancer Bcap37 in vivo and in vitro.

关 键 词：表皮生长因子 单克隆抗体 Her2 BCAP37 乳腺癌 抗肿瘤活性 

分 类 号：R965.1[医药卫生—药理学]